莫西沙星为基础的三联疗法根除幽门螺杆菌疗效观察

摘要

目的 观察莫西沙星为基础的三联疗法根除幽门螺杆菌(Hp)的效果.方法 共入选Hp感染的患者117例,根除方案中慢性胃炎者口服雷尼替丁枸橼酸铋,消化性溃疡者口服雷贝拉唑;以上两类患者各随机分为两组,含莫西沙星组同时服用阿莫西林或克拉霉素,对照组口服阿莫西林及克拉霉素.抗生素疗程结束后4周行13C呼气试验判断Hp的根除情况.结果 含莫西沙星组及对照组Hp的根除率在慢性胃炎患者中分别为72.4%、81.3%,在消化性溃疡患者中为80.0%、80.6%;各组间差别无统计学意义.慢性胃炎患者应用阿莫西林者Hp根除率明显高于应用克拉霉素者.结论 莫西沙星可以作为根除Hp的治疗用药;克拉霉素的耐药情况对Hp根除效果的影响较大.%Objective To evaluate the efficacy of Moxifloxacin-based triple therapies in the eradication of Helicobacter pylori (Hp) infection.Methods 117 cases with Hp infection were treated with ranitidine bismuth citrate for chronic gastritis, and with Rabeprazole for peptic ulcers.The above two classes of cases were randomly divided into two groups respectively.The moxifloxacin-based group was simultaneously treated with amoxicillin or clarithrornycin; the control group was treated with amoxicillin and clarithromycin.The eradication rates of Hp were evaluated by 13C-urea breath test 4 weeks after the treatment.Results The Hp eradication rates of the moxifloxacinbased group and the control group were 72.4％ and 81.3％ respectively in chronic gastritis patients, and 80.0％, 80.6％ in peptic ulcer patients.The eradication rates of Hp with amoxicillin were superior than clarithrornycin in the chronic gastritis patients (P=0.044).Conclusions The moxifloxacin-based triple therapy was considered as a new, effective,first-line therapy option.The resistance of clarithromycin affected the eradication rates of Hp very much.